Are you Dr. D'Andrea?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 56 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2910 Toll Gate Dr
East Norriton, PA 19403Phone+1 610-631-2652- Is this information wrong?
Summary
- Dr. Denise D'Andrea, MD is a nephrologist in East Norriton, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania, Ohio, and New York.
Education & Training
University of Pennsylvania Health SystemFellowship, Nephrology, 1993 - 1994- University of Pennsylvania Health SystemFellowship, Nephrology, 1991 - 1992
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1989 - 1990- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1987 - 1989
Georgetown University School of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 1990 - Present
NJ State Medical License 1988 - 2025
PA State Medical License 1990 - 2024
OH State Medical License 1990 - 1992
NY State Medical License 1990 - 1992
MD State Medical License 1990 - 1992
AL State Medical License Active through 1991- Join now to see all
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 13 citationsPharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.Michael A. Tortorici, Danielle Duffy, Rebecca Evans, John Feaster, Andreas Gille, Timothy G. K. Mant, Samuel D. Wright, Denise D'Andrea> ;Clinical Pharmacology in Drug Development. 2019 Jul 1
- 10 citationsModerate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.Andreas Gille, Danielle Duffy, Michael A. Tortorici, Samuel D. Wright, Lawrence I. Deckelbaum, Denise D'Andrea> ;Journal of Clinical Pharmacology. 2019 Mar 1
- 10 citationsEvaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.Paul A. Gurbel, Udaya S. Tantry, Denise D'Andrea, Thomas Chung, John H. Alexander, Kevin P. Bliden, Samuel D. Wright, Pierluigi Tricoci> ;Journal of Thrombosis and Thrombolysis. 2018 May 1
- Join now to see all
Professional Memberships
- Fellow
